Clinical Trial

Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Study acronym: FIL_COLUMN
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 5, 2026 (before its estimated March 21, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, phase 2, multicenter, open-label, single-arm study. Primary objective is to assess the efficacy of loncastuximab tesirine given as consolidation therapy after salvage immunochemotherapy in BTKi (Bruton Tyrosine Kinase inhibitors) -treated (or BTKi intolerant) R/R (Relapse or Refractory) MCL (Mantle Cell Lymphoma) patients. The sponsor of this clinical trial is Fondazione Italiana Linfomi - ETS (FIL ETS).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2022-02-21; most recent amendment 2025-12-31.
Status change: Not Yet Recruiting → Recruiting 2022-04-22
Trial Details
NCT Number NCT05249959
Lead Sponsor Fondazione Italiana Linfomi - ETS
Conditions Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Enrollment 49 participants
Start Date 2022-03-21
Primary Completion 2026-03-21 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-01-05